articleCurrent Diabetes ReportsJan 13, 2026HYBRID OA

SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes

ALAris LiakosTKThomas KaragiannisIAIoannis AvgerinosEBEleni Bekiari

Aristotle University of Thessaloniki

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE OF REVIEW: The pharmacologic management of type 2 diabetes prioritises sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists for their demonstrated cardiovascular benefits in individuals with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors, chronic kidney disease, and heart failure. However, while current guidelines recommend these drug classes alone, combination therapy is not explicitly advocated. Herein we summarise the rationale and available evidence in support for combination therapy. RECENT FINDINGS: , body weight, and blood pressure. More importantly, combination therapy can offer potential advantages for…

Citation impact

5
total citations
FWCI
70.10
Percentile
100%
References
47
Too recent for citation history.

Authors

4

Topics & keywords

Topics
Keywords
  • Combination therapy
  • Type 2 diabetes
  • Diabetes mellitus
  • Population
  • Disease
  • Pharmacotherapy
  • Clinical trial
No related works found for this paper.

Funding